What Is Sezime (Hibemib) Tablet Used For—and Which Lipid Levels Does It Target?

Sezime (hibemchol) tablets are a novel, first-in-class cholesterol absorption inhibitor approved in China for the management of hypercholesterolemia. Unlike statins—which inhibit endogenous cholesterol synthesis—or bile acid sequestrants—which interrupt enterohepatic circulation—hibemchol selectively targets the Niemann-Pick C1-like 1 (NPC1L1) protein in the jejunal brush border, thereby blocking intestinal uptake of dietary and biliary cholesterol.

Clinical evidence demonstrates that hibemchol significantly reduces low-density lipoprotein cholesterol (LDL-C), the primary atherogenic lipoprotein and principal target of lipid-lowering therapy. In pivotal phase III trials, monotherapy with hibemchol produced mean LDL-C reductions of approximately 18–22% from baseline. When added to stable statin regimens, it conferred additional LDL-C lowering of 15–20%, without increasing the risk of statin-associated myopathy or elevating liver transaminases.

Hibemchol is indicated as an adjunct to diet and maximally tolerated statin therapy in adult patients with primary hypercholesterolemia or mixed dyslipidemia who require further LDL-C reduction. It is not intended for use in familial hypercholesterolemia as monotherapy nor as a replacement for statins in high- or very-high cardiovascular risk populations unless statins are contraindicated or not tolerated.

Notably, hibemchol has a favorable safety profile: it is minimally absorbed systemically, exhibits no clinically relevant drug–drug interactions with commonly prescribed cardiovascular agents—including warfarin, antiplatelets, and antihypertensives—and does not require routine hepatic or renal monitoring. Its mechanism of action makes it particularly valuable in patients with statin intolerance or those needing incremental LDL-C lowering to achieve guideline-recommended targets.